We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk

By LabMedica International staff writers
Posted on 04 May 2026

High blood pressure during pregnancy is common and can progress to pre-eclampsia, making close monitoring at antenatal visits essential. More...

However, most risk assessment begins only after pregnancy has started. Identifying risk earlier could improve how care teams counsel patients and plan preventive strategies. New findings show that routine blood tests performed several years before pregnancy are associated with later risk of hypertension and pre-eclampsia.

Researchers at Karolinska Institutet (Stockholm, Sweden) analyzed pregestational cardiometabolic biomarkers measured during health examinations four to six years before a first pregnancy. The approach evaluates routinely collected indicators—blood sugar, blood lipids, haptoglobin as a marker of low‑grade inflammation, and the TyG index, described as reflecting impaired glucose metabolism—to stratify risk. Associations were assessed using the Stockholm-based AMORIS database and subsequent linkage to national registers.

The cohort comprised just over 35,000 women in Stockholm, Sweden, all expecting their first child. Baseline laboratory values came from health examinations conducted four to six years before conception, and pregnancy outcomes were ascertained from national registers. The investigation is described as an observational study and was published online on April 30, 2026, in JAMA Network Open.

Overall, 5.5% of participants developed high blood pressure or pre‑eclampsia during pregnancy. Depending on which biomarker was elevated, 5.5% to 12.8% of women with pregestational metabolic disturbances were affected, compared with 4.1% to 5.3% among women whose levels were within the normal range. Even moderately elevated levels of LDL cholesterol, triglycerides, apolipoprotein B, haptoglobin, and the TyG index were associated with increased risk.

The researchers note that the causes of pregnancy‑related hypertension are complex and not fully understood. Because the study is observational, the results should be interpreted with caution and do not establish causality. Next steps include evaluating whether early abnormalities in blood sugar, lipids, and inflammation predict other outcomes such as gestational diabetes and preterm birth, and examining links with women’s long‑term cardiovascular health.=

“Our results suggest that the increased risk may begin even at levels currently considered normal. This means that routine blood tests could be used as an additional tool to help healthcare professionals assess risk and discuss lifestyle with women of childbearing age, both before and early in pregnancy,” said Karin Leander, senior lecturer and associate professor at the Institute of Environmental Medicine, Karolinska Institutet.

Related Links
Karolinska Institutet


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.